PreciseDx, a cancer risk stratification company that provides patient-specific risk information through analysis of morphology features, raised $10.8 million in Series A funding, per Fortune’s Term Sheet. Merck Global Health Innovation Fund led the round and was joined by investors including the Mount Sinai Health System, Agilent Technologies, IBM Ventures, and the Hobart Group.
Cancer-Risk Assessment Firm PreciseDx Raises $10.8M in A Round
